“FDA advisory panel declines to support a controversial Alzheimer’s treatment,” is a news article that is concerned with convening at a request of scientists and clinicians by the FDA on reviewing the evidence for aducanumab, which refers to a drug that targets a protein called amyloid-beta that is accumulated in the brains of people living with Alzheimer. The article was written by Laura Fenders on November 6, 2020. According to research done, the subsets of participants who receive sufficiently high doses of aducanumab show benefits in both a trial trending positive and the other that shows no benefits from aducanumab.This paper describes concise terms of the problem being investigated by the article, describes the details of the experimental method used in the study and describes each relevant result originating from the study. Besides, the paper focuses on my specific conclusions from the study.
The “FDA advisory panel declines to support a controversial Alzheimer’s treatment” news article investigates the uncertain fate of a potential new Alzheimer’s drug. Previous research is done about the drug; it follows that there lacks evidence about the drug’s ineffectiveness (Fenders 1). Scientists and clinicians claim that subsets of participants who receive sufficiently high doses of aducanumab show benefits in both a trial trending positive and the other that shows no benefits from aducanumab. As a result, clinicians and scientists have been convened at FDA request to review evidence for Aducanumab, which refers to a drug that aims a protein that accumulates brains of individuals with Alzheimer called amyloid-beta. Afterward, they have revealed that the drug is designed to stick to A-beta and stop it from forming more dangerous and larger clumps that though not stopping or reversing it, slows down its progression.
Besides, this article uses certain experimental methods, among them asking questions to respondents. The news article researchers asked eleven experts whether the clinical study provided concrete evidence about the effectiveness of treating Alzheimer’s. Eight of the experts did not answer the question; one said yes, and two were not certain, indicating that their results were based on respondents’ answers. For instance, they asked neuroscientist and neurologist Arjun Masukar of the Langone’s Alzheimer’s disease research center based at New York University about the approval of the drug, and he answered that “ if approved aducanumab would become the first drug that actually underlines Alzheimer and slows down its progression.”(Fenders 2) Besides, their research methods incorporated clinical trials to ascertain the aducanumab drug’s effectiveness in treating Alzheimer’s. The FDA is bound not to follow guidelines committee recommendations as they previously for a reason not stated. However, the two large clinical trials of aducanumab gave different results, one negative and one positive. The results obtained from the trials followed that aducanumab’s ability to treat Alzheimer’s cannot be proved by clinical trials that give divergent results. They thus paused the trials and wrote an article that said, “The drug should be tested again with different clinical trials, those researchers say because the analysis results that sated the drug did not work.
The study of the aducanumab drug for the treatment of Alzheimer’s had several results attached to their deep research. One of the pertinent results was that evidence about the aducanumab drug not working was not convincing enough (Fenders 1). Carrying out clinical trials on the aducanumab drug and getting divergent results, by the article published by Alzheimer’s and Dementia, trial failures should not be evidence that the drug cannot treat Alzheimer’s researchers should test the drug again using other distinct clinical trials. The reason for these results about the fate of the drug effectiveness is that probably many errors related to the effectiveness of the drug are with the trials and nit the drug because, during production, the drug was properly designated without errors on how it would stick to the A-beta and stop it from forming more dangerous and larger clumps thus slowing the disease’s progression.
Another pertinent result from the research is that certainty of what Alzheimer’s disease would cause too many Americans absent treatment is more than the uncertainty in trial errors among the scientific community (Fenders 2). In dealing with the drug’s fate, its beneficial effects are much than the uncertainties associated with the scientific trials. Therefore, it follows that the drug is important for the treatment of Alzheimer as explained by scientists and clinicians like neuroscientists and neurologist who says that if the drug is approved, it can be a milestone of the first therapy that aims Alzheimer and slows its progression.
The specific conclusion from the FDA’s research is that errors in scientific trials cannot be any evidence of stopping usage of a certain drug whose health proposed benefits might be more. According to the letter sent to the FDA by a non-profit organization urging them to approve the aducanumabs’ drug, it is evident that some drugs being used in hospitals might not have been effectively tried and proven right. Still, health organizations use them, basing their arguments on a believed benefit. For instance, the letter states that “before rejecting approval they must weigh the certainty of diseases to millions of Americans absent treatment with the uncertainty of trials in the scientific group.”(Fenders 2)